Medicxi has merged six of its dermatology-focused companies to form Alys Pharmaceuticals, which will develop novel therapies in the immuno-dermatology space, the new Boston and Swiss-based biotech announced Monday.
Tag Archive for: Medicxi
The new financing will help the Boston-based biotech accelerate the development of its siRNA-based therapies for immuno-dermatology indications.
With financial backing from Medicxi, Vaderis Therapeutics AG emerged from stealth mode Monday with a focus on allosteric AKT inhibitors and a clinic-ready drug candidate.